Please use this identifier to cite or link to this item: https://scidar.kg.ac.rs/handle/123456789/11347
Title: Nonalcoholic fatty liver disease in patients with polycystic ovary syndrome
Authors: Macut D.
Bjekic-Macut J.
Livadas S.
Stanojlovic O.
Hrncic D.
Rasic Markovic, Aleksandra
Milutinović D.
Mladenovic, Vladimir
Andric Z.
Journal: Current Pharmaceutical Design
Issue Date: 1-Jan-2018
Abstract: © 2018 Bentham Science Publishers. Polycystic ovary syndrome (PCOS) is the most common endocrine disease in women during the reproductive period. True PCOS phenotype is prone to develop metabolic consequences during life. Obese PCOS women with insulin resistance are carrying a risk for developing type 2 diabetes, and influencing liver function by generating liver steatosis and nonalcoholic fatty liver disease (NAFLD). Moreover, serum testosterone of over 3 nmol/L is associated with at least two-fold higher risk for the development of NAFLD in PCOS women. Numerous genes involved in the pathogenesis of hyperandrogenism, insulin resistance and inflammation are associated with the development of NAFLD in PCOS women. Liver biopsy is not considered as the first line procedure for the diagnosis of liver damage in a prevalent condition as PCOS. Therefore, simple and reliable surrogate markers as serum aminotransferases levels or surrogate indexes (i.e. fatty liver index and NAFLD-fatty liver score) could be used for the assessment of fatty liver in PCOS women. First line therapeutic approach for NAFLD in PCOS includes a change in lifestyle that implies dietary regiment and physical activity but without well-defined protocols. Second line therapy considers addition of drugs on the established lifestyle change. Metformin remains the drug of choice for reduction of insulin resistance and liver enzymes level. Liraglutide, glucagon-like peptide-1 receptor agonists, showed favorable effects on the reduction of liver fat content and visceral adipose tissue in overweight women with PCOS. Current review analyzes the impact of metabolic risk factors, diagnostic approach and management options on NAFLD in women with PCOS.
URI: https://scidar.kg.ac.rs/handle/123456789/11347
Type: Review
DOI: 10.2174/1381612825666190117100751
ISSN: 13816128
SCOPUS: 85063258855
Appears in Collections:University Library, Kragujevac
[ Google Scholar ]

Page views(s)

13

Files in This Item:
File Description SizeFormat 
PaperMissing.pdf
  Restricted Access
29.86 kBAdobe PDFThumbnail
View/Open Request a copy


Items in SCIDAR are protected by copyright, with all rights reserved, unless otherwise indicated.